Innate Pharma (IPHA)

• Market cap: $148M
• 1 day: 4.14%
• 5 days: -3.30%
• 1 month: -16.19%
• 3 months: -8.33%
• 6 months: -18.52%
• Year to date: -5.88%
• 1 year: -33.83%
• 5 years: -76.56%
• 10 years: -70.91%

About: Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Employees: 179

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 8 [Q2] → 8 (+0) [Q3]

0.06% less ownership

Funds ownership: 0.35% [Q2] → 0.29% (-0.06%) [Q3]

1% less capital invested

Capital invested by funds: $554K [Q2] → $545K (-$8.21K) [Q3]

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $11.50 553% upside
• Avg. target: $11.50 553% upside
• High target: $11.50 553% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 31% 1-year accuracy 58 / 186 met price target

553% upside $11.50

Buy Reiterated

17 Jan 2025